TABLE 3.
Challenge group | Neutralizing antibody
responsea
|
Protection? | ||
---|---|---|---|---|
TCLA SIVmac251 | Primary SIVmac251 | Cloned SIVmac239 | ||
5 week | ||||
1472 | 231 | 15 | <4 | No |
1474 | 304 | 9 | <4 | No |
1476 | 1,093 | <4 | <4 | No |
1478 | 1,014 | 9 | <4 | No |
1480b | <20 | <4 | <4 | No |
10 week | ||||
1482 | 1,499 | 22 | 9 | No |
1484 | 409 | 29 | 10 | No |
1488 | 2,613 | 8 | 7 | Yes |
1490 | 1,549 | <4 | 10 | Yes |
1492b | <20 | <4 | <4 | No |
15 week | ||||
1494 | 3,288 | 22 | 26 | Yes |
1496 | 3,904 | 25 | 10 | Yes |
1498 | 898 | <4 | <4 | Yes |
1502 | 350 | <4 | <4 | Yes |
1504b | <20 | <4 | <4 | No |
25 week | ||||
1506 | 774 | 9 | 16 | Yes |
1510 | 3,625 | <4 | 29 | No |
1512 | 2,747 | <4 | 20 | Yes |
1514 | 9,039 | 74 | 23 | Yes |
1516b | <20 | <4 | <4 | No |
Reciprocal serum dilution to yield a 50% reduction in virus-induced cell killing in CEMx174 cells.
Nonimmunized control animal.